EpicentRx

NCT05566041

Phase 3, Active, not recruiting, 2022, 292 people, 4 Oct 2022, clinicaltrials.gov

NCT03699956

Phase 3, Terminated, 2018, 18 people, 9 Oct 2018, clinicaltrials.gov

NCT02489903

Phase 2, Completed, 2015, 139 people, 3 Jul 2015, clinicaltrials.gov